Poster Presentation on Combination Therapy for Patients with Metastatic Gastric Cancer
Idience, a new drug development company under the Il-Dong Pharmaceutical Group, announced on May 29 that it will present clinical research results on combination therapy using its PARP inhibitor class anticancer drug candidate, Benadaparib, at the American Society of Clinical Oncology (ASCO) annual meeting.
The ASCO annual meeting is the largest event in the field of oncology, attended by oncologists, researchers, and professionals from the medical and industrial sectors worldwide. This year, it is scheduled to be held in Chicago, United States, from May 30 to June 3.
At this conference, Idience will present research findings in poster format from an exploratory analysis of a multinational phase 1b/2a clinical trial (NCT04725994) investigating the combination therapy of Benadaparib and irinotecan in patients with metastatic gastric cancer (mGC) who have undergone three or more prior lines of therapy.
Idience is developing a new anticancer treatment for metastatic gastric cancer after three or more lines of therapy by combining Benadaparib, a PARP inhibitor with a novel mechanism, and irinotecan, an established chemotherapeutic agent. According to the company, there is significant unmet demand for new treatments in this indication, as the median progression-free survival (mPFS) for standard therapy is only two months.
According to Idience, the combination therapy using Benadaparib demonstrated a meaningful association between efficacy in metastatic gastric cancer patients and the presence of homologous recombination deficiency (HRD) gene mutations. In particular, patients with HRD gene mutations showed even greater potential benefit.
In the phase 1b/2a clinical trial of Benadaparib and irinotecan combination therapy, the median progression-free survival (mPFS) was 4.2 months (95% CI: 2.9-5.5), and the median overall survival (mOS) was 8.0 months (95% CI: 6.7-11.4).
Additionally, in a subgroup of patients with homologous recombination deficiency, including those with ATM or BRCA1/2 mutations, the mPFS was 8.3 months (95% CI: 1.2-23.6) and the mOS was 9.9 months (95% CI: 6.7-33.9). Adverse events were observed at similar levels regardless of HRD status.
Lee Wonsik, CEO of Idience, stated, "Being selected as a presentation topic at the world's most prestigious conference in clinical oncology further highlights the competitiveness of Benadaparib and the potential for developing new anticancer therapies."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
